Could The NHS Really Sell Its Data For $12 Billion?

A new report by consulting firm EY suggests that if the U.K. National Health Service (NHS) datasets were put to use, their value could be up to £9.6 billion ($12 billion) per year. This data is held within 55 million patient records and according to the report, a typical electronic health record is worth about £100 ($125), while one that’s linked to detailed genomic data can fetch as much as £5,000 ($6,200). That means an overall value of £5 billion ($6.2 billion) to commercial partners and £4.6 billion ($5.7 billion) per year in health economic benefits to patients.

Read the full article on Forbes.

New Study Shows This Bracelet Knows When Women Are Most Fertile

Innovating in healthcare isn’t easy. At one end of healthcare, where the combination of systems, processes, software, hardware and quick human decisions mean life or death, real innovation is tough. You can’t “move fast and break things,” “disrupt,” or, to go beyond startup cliches, actually stop processes to introduce something new and revert if it doesn’t work out, otherwise people might pay the ultimate price.

At the other end of healthcare, where consumers are buying products to optimize their health and/or prevent disease, the risk of a product failing isn’t morbidity or mortality, which creates space to fail and therefore to innovate. As such, we’re currently seeing a big swell in B2C business models for products that prevent disease and optimize health and the line between health and fitness is certainly blurring – take Peloton’s recent IPO filing as a good example.

Read the full article on Forbes.

Tech Companies Respond To The Opioid Crisis Whilst Pharma Executives Face Criminal Charges

According to The National Institute on Drug Abuse, more than 130 people in the United States die every day from overdosing on opioids, a class of prescription, pain-relieving medications that include heroin, fentanyl morphine and tramadol, among others. The knock on effects of the mass-addiction facing huge amounts of our global population go far beyond the individuals, to public health systems and social and economic welfare. According to the CDC and Prevention, the economic burden of prescription opioid misuse in the United States, is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment and criminal justice involvement.

Read the full article on Forbes.

How One Patient-Entrepreneur Is Impacting 100M Patients Worldwide

Robin Farmanfarmaian is a healthtech expert, angel investor, global speaker and author of Amazon No.1 bestseller The Patient as CEO: How Technology Empowers the Healthcare Consumer. She’s backed companies like Dance Biopharm who are doing clinical trials for an inhaled insulin vaporized from a liquid, and unicorn MindMaze VR who have raised >$100M (in part from Leonardo di Caprio) and are valued at $1 billion. I spoke to Robin about living with autoimmune disease and why she became motivated to positively impact 100M patients worldwide through healthtech innovation.

Read the full article on Forbes.